头孢哌酮、头孢噻肟、拉氧头孢和羧苄西林与妥布霉素联合应用对铜绿假单胞菌的比较协同活性。
Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
作者信息
Mintz L, Drew W L
出版信息
Antimicrob Agents Chemother. 1981 Feb;19(2):332-4. doi: 10.1128/AAC.19.2.332.
Abstract
A broth dilution checkerboard synergy assay was used to assess the activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, in combination with tobramycin, against 38 strains of Pseudomonas aeruginosa. Synergy occurred significantly more often (P less than 0.001) when tobramycin was combined with cefotaxime (63%) than when it was combined with carbenicillin (26%), cefoperazone (21%), or moxalactam (18%). Of the 25 synergistically inhibited strains, the combination cefotaxime-tobramycin was synergistic against 24 and was the only synergistic combination against 10. Of six strains initially resistant to cefotaxime, five were susceptible to this agent (minimum inhibitory concentration, less than or equal to 32 micrograms/ml) when it was combined with tobramycin. Clinical trials are needed to determine the therapeutic efficacy of cefotaxime-aminoglycoside combinations in the treatment of serious Pseudomonas infections.
摘要
采用肉汤稀释棋盘协同试验，评估头孢哌酮、头孢噻肟、拉氧头孢和羧苄西林分别与妥布霉素联合对38株铜绿假单胞菌的活性。与羧苄西林（26%）、头孢哌酮（21%）或拉氧头孢（18%）联合相比，妥布霉素与头孢噻肟联合时协同作用显著更常见（P<0.001）（63%）。在25株被协同抑制的菌株中，头孢噻肟-妥布霉素组合对24株具有协同作用，且是10株菌株唯一的协同组合。最初对头孢噻肟耐药的6株菌株中，5株在与妥布霉素联合时对该药物敏感（最低抑菌浓度≤32μg/ml）。需要进行临床试验以确定头孢噻肟-氨基糖苷类药物联合治疗严重铜绿假单胞菌感染的疗效。
相似文献
1
Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1981 Feb;19(2):332-4. doi: 10.1128/AAC.19.2.332.
2
Susceptibility of Pseudomonas aeruginosa to cefoperazone, cefotaxime and moxalactam, with special reference to isolates resistant to aminoglycosides, carbenicillin and ticarcillin.
J Antimicrob Chemother. 1981 Sep;8(3):205-11. doi: 10.1093/jac/8.3.205.
3
Comparison of the beta-lactamase stability and the in-vitro activity of cefoperazone, cefotaxime, cefsulodin, ceftazidime, moxalactam and ceftriaxone against Pseudomonas aeruginosa.
J Antimicrob Chemother. 1981 Oct;8(4):323-31. doi: 10.1093/jac/8.4.323.
4
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.
Am J Med. 1986 Jun 30;80(6B):126-37. doi: 10.1016/0002-9343(86)90490-0.
5
Comparative activity of cefotaxime and selected beta-lactam antibiotics against Haemophilus influenzae and aerobic gram-negative bacilli.
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S401-5. doi: 10.1093/clinids/4.supplement_2.s401.
6
A study of cefoperazone alone and in combination with tobramycin against Pseudomonas aeruginosa.
Clin Ther. 1980;3(Spec Issue):134-8.
7
Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin.
J Antimicrob Chemother. 1983 Oct;12(4):337-45. doi: 10.1093/jac/12.4.337.
8
Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1980 Dec;18(6):893-6. doi: 10.1128/AAC.18.6.893.
9
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
Antimicrob Agents Chemother. 1980 Apr;17(4):750-6. doi: 10.1128/AAC.17.4.750.
10
Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and aminoglycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa.
J Antimicrob Chemother. 1980 Jul;6(4):471-7. doi: 10.1093/jac/6.4.471.
引用本文的文献
1
Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.
Antimicrob Agents Chemother. 1982 Dec;22(6):985-9. doi: 10.1128/AAC.22.6.985.
2
Comparative in vitro activities of beta-lactam-tobramycin combinations against Pseudomonas aeruginosa and multidrug-resistant gram-negative enteric bacilli.
Antimicrob Agents Chemother. 1982 Jun;21(6):1003-6. doi: 10.1128/AAC.21.6.1003.
3
In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates.
Antimicrob Agents Chemother. 1984 Apr;25(4):401-4. doi: 10.1128/AAC.25.4.401.
4
In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1984 Apr;25(4):534-6. doi: 10.1128/AAC.25.4.534.
5
Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1983 Oct;26(4):279-333. doi: 10.2165/00003495-198326040-00001.
6
Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
Drugs. 1983 Mar;25(3):223-89. doi: 10.2165/00003495-198325030-00001.
7
Comparative in vitro activities of azlocillin-cefotaxime and azlocillin-tobramycin combinations against blood and multi-drug resistant bacterial isolates.
Antimicrob Agents Chemother. 1982 Jul;22(1):167-9. doi: 10.1128/AAC.22.1.167.
8
Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1983 Jan;23(1):179-81. doi: 10.1128/AAC.23.1.179.
9
Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.
Antimicrob Agents Chemother. 1982 Apr;21(4):673-5. doi: 10.1128/AAC.21.4.673.
10
In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1986 Jul;30(1):25-30. doi: 10.1128/AAC.30.1.25.
本文引用的文献
1
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.
Antimicrob Agents Chemother. 1980 Jul;18(1):88-93. doi: 10.1128/AAC.18.1.88.
2
Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia.
N Engl J Med. 1971 May 13;284(19):1061-5. doi: 10.1056/NEJM197105132841904.
3
The use of combinations of antimicrobial drugs.
Annu Rev Pharmacol. 1968;8:151-70. doi: 10.1146/annurev.pa.08.040168.001055.
4
Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin.
J Infect Dis. 1974 Feb;129(2):124-33. doi: 10.1093/infdis/129.2.124.
5
Clinical significance of in vitro synergism between antibiotics in gram-negative infections.
Antimicrob Agents Chemother. 1972 Dec;2(6):470-5. doi: 10.1128/AAC.2.6.470.
6
Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin.
J Infect Dis. 1977 Sep;136(3):327-35. doi: 10.1093/infdis/136.3.327.
7
Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.
Antimicrob Agents Chemother. 1976 Oct;10(4):646-51. doi: 10.1128/AAC.10.4.646.
8
Antimicrobial synergism--an elusive concept.
J Infect Dis. 1979 Oct;140(4):639-41. doi: 10.1093/infdis/140.4.639.
9
Comparison of techniques for measurement of in vitro antibiotic synergism.
J Infect Dis. 1979 Oct;140(4):629-33. doi: 10.1093/infdis/140.4.629.
10
Significance of antimicrobial synergism for the outcome of gram negative sepsis.
Am J Med Sci. 1977 Mar-Apr;273(2):157-67. doi: 10.1097/00000441-197703000-00005.
Zotero 插件